Nix DE - Search Results

1

Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Peloquin CA, et al. Among authors: nix de. Arch Intern Med. 1989 Oct;149(10):2269-73. Arch Intern Med. 1989. PMID: 2508586

2

Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.

Nix DE, Sands MF, Peloquin CA, Vari AJ, Cumbo TJ, Vance JW, Fracasso JE, Schentag JJ. Nix DE, et al. Am J Med. 1987 Apr 27;82(4A):352-6. Am J Med. 1987. PMID: 3555060 Clinical Trial.

3

Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.

Hyatt JM, Nix DE, Schentag JJ. Hyatt JM, et al. Among authors: nix de. Antimicrob Agents Chemother. 1994 Dec;38(12):2730-7. doi: 10.1128/AAC.38.12.2730. Antimicrob Agents Chemother. 1994. PMID: 7695254 Free PMC article.

4

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.

Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, Schentag JJ. Goss TF, et al. Among authors: nix de. Ann Pharmacother. 1994 Jul-Aug;28(7-8):863-8. doi: 10.1177/106002809402800707. Ann Pharmacother. 1994. PMID: 7949501

5

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.

Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ. Forrest A, et al. Among authors: nix de. Antimicrob Agents Chemother. 1993 May;37(5):1065-72. doi: 10.1128/AAC.37.5.1065. Antimicrob Agents Chemother. 1993. PMID: 8517693 Free PMC article. Clinical Trial.

6

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Forrest A, et al. Among authors: nix de. Antimicrob Agents Chemother. 1993 May;37(5):1073-81. doi: 10.1128/AAC.37.5.1073. Antimicrob Agents Chemother. 1993. PMID: 8517694 Free PMC article. Clinical Trial.

7

Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose.

Birmingham MC, Guarino R, Heller A, Wilton JH, Shah A, Hejmanowski L, Nix DE, Schentag JJ. Birmingham MC, et al. Among authors: nix de. J Antimicrob Chemother. 1999 Mar;43 Suppl A:43-8. doi: 10.1093/jac/43.suppl_1.43. J Antimicrob Chemother. 1999. PMID: 10225571

8

Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Schentag JJ, Nix DE, Adelman MH. Schentag JJ, et al. Among authors: nix de. DICP. 1991 Oct;25(10):1050-7. doi: 10.1177/106002809102501003. DICP. 1991. PMID: 1803788

9

Effect of lomefloxacin on theophylline pharmacokinetics.

Nix DE, Norman A, Schentag JJ. Nix DE, et al. Antimicrob Agents Chemother. 1989 Jul;33(7):1006-8. doi: 10.1128/AAC.33.7.1006. Antimicrob Agents Chemother. 1989. PMID: 2675751 Free PMC article.

10

Sucralfate reduces the gastrointestinal absorption of norfloxacin.

Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ. Parpia SH, et al. Among authors: nix de. Antimicrob Agents Chemother. 1989 Jan;33(1):99-102. doi: 10.1128/AAC.33.1.99. Antimicrob Agents Chemother. 1989. PMID: 2712548 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters